{"id":67450,"date":"2026-06-05T14:17:55","date_gmt":"2026-06-05T06:17:55","guid":{"rendered":"https:\/\/flcube.com\/?p=67450"},"modified":"2026-06-05T14:17:56","modified_gmt":"2026-06-05T06:17:56","slug":"chinas-nhc-releases-sixth-pediatric-drug-priority-list-27-varieties-including-emicizumab-pembrolizumab-and-omalizumab-targeted-for-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67450","title":{"rendered":"China&#8217;s NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China&#8217;s <strong>National Healthcare Commission (NHC)<\/strong> announced the release of its <strong>sixth batch of pediatric drugs encouraged for research and development<\/strong>, adding <strong>27 therapeutic varieties<\/strong> to the national priority list designed to address critical gaps in children&#8217;s medicine availability.<\/p>\n\n\n\n<h2 id=\"h-regulatory-initiative-overview\" class=\"wp-block-heading\">Regulatory Initiative Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Issuing Authority<\/strong><\/td><td>National Healthcare Commission (NHC) &#8211; China<\/td><\/tr><tr><td><strong>Batch Number<\/strong><\/td><td>Sixth official pediatric drug priority list<\/td><\/tr><tr><td><strong>Total Varieties<\/strong><\/td><td>27 distinct therapeutic agents<\/td><\/tr><tr><td><strong>Policy Objective<\/strong><\/td><td>Address unmet medical needs in pediatric populations<br>Accelerate development and approval of age-appropriate formulations<br>Improve access to essential medicines for children<\/td><\/tr><tr><td><strong>Implementation Framework<\/strong><\/td><td>Incentives include expedited review pathways, extended market exclusivity, and preferential reimbursement consideration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-priority-drug-portfolio-analysis\" class=\"wp-block-heading\">Priority Drug Portfolio Analysis<\/h2>\n\n\n\n<h3 id=\"h-oncology-amp-hematology-agents\" class=\"wp-block-heading\">Oncology &amp; Hematology Agents<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Emicizumab<\/strong> \u2013 Hemophilia A prophylaxis<\/li>\n\n\n\n<li><strong>Tagraxofusp<\/strong> \u2013 Blastic plasmacytoid dendritic cell neoplasm<\/li>\n\n\n\n<li><strong>Calaspargase pegol<\/strong> \u2013 Acute lymphoblastic leukemia<\/li>\n\n\n\n<li><strong>Trametinib<\/strong> \u2013 BRAF-mutant cancers<\/li>\n\n\n\n<li><strong>Dabrafenib<\/strong> \u2013 BRAF-mutant cancers<\/li>\n\n\n\n<li><strong>Pembrolizumab<\/strong> \u2013 Pediatric solid tumors and lymphomas<\/li>\n\n\n\n<li><strong>Nivolumab<\/strong> \u2013 Pediatric oncology indications<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-immunology-amp-allergy-therapeutics\" class=\"wp-block-heading\">Immunology &amp; Allergy Therapeutics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Etanercept<\/strong> \u2013 Juvenile idiopathic arthritis, psoriasis<\/li>\n\n\n\n<li><strong>Omalizumab<\/strong> \u2013 Pediatric asthma, chronic urticaria<\/li>\n\n\n\n<li><strong>Peanut allergen<\/strong> \u2013 Food allergy immunotherapy<\/li>\n\n\n\n<li><strong>Thiamazole<\/strong> \u2013 Pediatric hyperthyroidism<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-cardiovascular-amp-critical-care\" class=\"wp-block-heading\">Cardiovascular &amp; Critical Care<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sacubitril + valsartan<\/strong> \u2013 Pediatric heart failure<\/li>\n\n\n\n<li><strong>Epinephrine<\/strong> \u2013 Anaphylaxis, cardiac arrest<\/li>\n\n\n\n<li><strong>Hydrocortisone<\/strong> \u2013 Adrenal insufficiency, inflammatory conditions<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-neurology-amp-psychiatry\" class=\"wp-block-heading\">Neurology &amp; Psychiatry<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Viloxazine<\/strong> \u2013 Attention-deficit\/hyperactivity disorder (ADHD)<\/li>\n\n\n\n<li><strong>Lithium carbonate<\/strong> \u2013 Pediatric bipolar disorder<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-respiratory-amp-gastrointestinal\" class=\"wp-block-heading\">Respiratory &amp; Gastrointestinal<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Formoterol + mometasone<\/strong> \u2013 Asthma maintenance therapy<\/li>\n\n\n\n<li><strong>Pantoprazole<\/strong> \u2013 Gastroesophageal reflux disease, peptic ulcers<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Multinational Pharma<\/strong><\/td><td>Opportunity to expand existing products into Chinese pediatric markets<br>Potential for premium pricing and accelerated approval timelines<br>Requirement to develop age-appropriate formulations<\/td><\/tr><tr><td><strong>Domestic Chinese Companies<\/strong><\/td><td>Priority access to expedited regulatory pathways<br>Government support for clinical trial infrastructure<br>Preferential procurement consideration in public hospitals<\/td><\/tr><tr><td><strong>Healthcare Providers<\/strong><\/td><td>Improved access to evidence-based pediatric treatments<br>Standardization of care across different regions<br>Enhanced treatment options for rare pediatric conditions<\/td><\/tr><tr><td><strong>Patients &amp; Families<\/strong><\/td><td>Reduced treatment delays and improved outcomes<br>Access to innovative therapies previously unavailable for children<br>Potential cost savings through government-negotiated pricing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-commercial-opportunities\" class=\"wp-block-heading\">Commercial Opportunities<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size:<\/strong> China&#8217;s pediatric pharmaceutical market valued at \u00a580-100 billion ($11-14 billion) annually<\/li>\n\n\n\n<li><strong>Growth Trajectory:<\/strong> 12-15% annual growth driven by policy support and increasing healthcare access<\/li>\n\n\n\n<li><strong>Reimbursement Advantage:<\/strong> Priority list inclusion supports favorable positioning in national reimbursement drug list (NRDL) negotiations<\/li>\n\n\n\n<li><strong>Development Incentives:<\/strong> Extended data exclusivity periods and reduced regulatory fees for priority pediatric indications<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Opportunities for international companies to partner with domestic firms for local development and commercialization<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory policy impacts, market opportunities, and commercial expectations. Actual results may differ due to risks including implementation timelines, competitive dynamics, and policy evolution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[60,68],"class_list":["post-67450","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-nhc-nhfpc","tag-pediatric-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs encouraged for research and development, adding 27 therapeutic varieties to the national priority list designed to address critical gaps in children&#039;s medicine availability.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67450\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs encouraged for research and development, adding 27 therapeutic varieties to the national priority list designed to address critical gaps in children&#039;s medicine availability.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67450\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T06:17:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T06:17:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67450#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67450\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development\",\"datePublished\":\"2026-06-05T06:17:55+00:00\",\"dateModified\":\"2026-06-05T06:17:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67450\"},\"wordCount\":423,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NHC (NHFPC)\",\"Pediatric drugs\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67450#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67450\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67450\",\"name\":\"China's NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T06:17:55+00:00\",\"dateModified\":\"2026-06-05T06:17:56+00:00\",\"description\":\"China's National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs encouraged for research and development, adding 27 therapeutic varieties to the national priority list designed to address critical gaps in children's medicine availability.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67450#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67450\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67450#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs encouraged for research and development, adding 27 therapeutic varieties to the national priority list designed to address critical gaps in children's medicine availability.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67450","og_locale":"en_US","og_type":"article","og_title":"China's NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development","og_description":"China's National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs encouraged for research and development, adding 27 therapeutic varieties to the national priority list designed to address critical gaps in children's medicine availability.","og_url":"https:\/\/flcube.com\/?p=67450","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T06:17:55+00:00","article_modified_time":"2026-06-05T06:17:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67450#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67450"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development","datePublished":"2026-06-05T06:17:55+00:00","dateModified":"2026-06-05T06:17:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67450"},"wordCount":423,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NHC (NHFPC)","Pediatric drugs"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67450#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67450","url":"https:\/\/flcube.com\/?p=67450","name":"China's NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T06:17:55+00:00","dateModified":"2026-06-05T06:17:56+00:00","description":"China's National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs encouraged for research and development, adding 27 therapeutic varieties to the national priority list designed to address critical gaps in children's medicine availability.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67450#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67450"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67450#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s NHC Releases Sixth Pediatric Drug Priority List \u2013 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67450"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67450\/revisions"}],"predecessor-version":[{"id":67452,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67450\/revisions\/67452"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}